Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of a Phase III clinical study for its salfaprodil injection, which is being developed as a treatment for acute ischemic stroke. Salfaprodil is a novel NMDA receptor antagonist. According to the public data, Apeloa first filed a clinical trial application for the drug in January 2012 and received trial approval in July 2014. Originally developed by South Korea-based GNT Pharma, Apeloa holds all intellectual property rights for China under a 2009 agreement, and in 2011, GNT Pharma licensed the compound to Toyota Tsusho for use in Japan.
The company cited COVID-19 disruptions as posing potential risks to the integrity and accuracy of clinical research data, as well as possible data quality issues due to protocol deviations, leading to the decision to end the Phase III study. Apeloa has stated that the cancellation will not affect other ongoing clinical studies.- Flcube.com
